Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 4/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 4/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 3/20 | 0.40 |
| ▸ | IL2 | P60568 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 3/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12156361 | 0.92 | STIM1 (0.52) | STIM1ORAI1ORAI2ABL1IL2 | |
| SCHEMBL12155461 | 0.85 | STIM1 (0.58) | STIM1ORAI1ORAI2IL2DEGS1 | |
| SCHEMBL12155794 | 0.85 | STIM1 (0.58) | STIM1ORAI1ORAI2ABL1IL2 | |
| SCHEMBL12156258 | 0.82 | STIM1 (0.43) | STIM1ORAI1ORAI2ABL1IL2 | |
| SCHEMBL12156364 | 0.79 | STIM1 (0.65) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL1701956 | 0.76 | STIM1 (0.66) | STIM1ORAI1ORAI2ABL1IL2 | |
| SCHEMBL12156206 | 0.76 | STIM1 (0.54) | STIM1ORAI1ORAI2ABL1IL2 | |
| SCHEMBL1701649 | 0.76 | STIM1 (0.67) | STIM1ORAI1ORAI2ABL1IL2 | |
| SCHEMBL16572602 | 0.74 | STIM1 (0.46) | STIM1ORAI1ORAI2ABL1IL2 | |
| SCHEMBL16572608 | 0.74 | STIM1 (0.46) | STIM1ORAI1ORAI2ABL1IL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-2563776-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-8980629-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.